Search

Displaying results 1341 - 1350 of 1571 in total
  1. Drug

    Lipoic acid

    go.drugbank.com/drugs/DB00166
    ApprovedInvestigationalNutraceutical

    A vitamin-like antioxidant.

    Mixtures: Strovite One CapletsCategories: Vitamin B Complex
  2. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.

  3. Drug

    Clocapramine

    go.drugbank.com/drugs/DB09003
    Experimental

    Clocapramine has been implicated in at least one strange death, including a suicide.

  4. Drug

    Tetryzoline

    go.drugbank.com/drugs/DB06764
    Approved

    Tetryzoline, also known as tetrahydrozoline, is a derivative of imidazoline with central and peripheral alpha (α)-adrenergic properties. Available since the 1950s, tetryzoline is a selective α1-receptor agonist that is used as an ocular ...

    Mixtures: Rohto All-In-One, Care One Eye Drops Seasonal Relief
  5. Drug

    AOD9604

    go.drugbank.com/drugs/DB06388
    Experimental

    AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.

  6. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders.

  7. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for ...

  8. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by mod...

  9. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019.

  10. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.